Paid Clinical Trials Milwaukee
Discover 768 paid clinical trials in Milwaukee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT03661866
Conditions
Atopic Dermatitis
Alopecia Areata
Hidradenitis Suppurativa
Vitiligo
Psoriasis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT05111574
Conditions
Anal Melanoma
Bladder Melanoma
Cervical Melanoma
Esophageal Melanoma
Gallbladder Melanoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Bone Scan
Cabozantinib S-malate
Computed Tomography
Echocardiography
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Sponsor:
Bristol-Myers Squibb
Location:
Code:
NCT06003426
Conditions
Idiopathic Pulmonary Fibrosis
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
BMS-986278
BMS-986278 Placebo
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
Sponsor:
Kartos Therapeutics, Inc.
Location:
Code:
NCT03662126
Conditions
Primary Myelofibrosis (PMF)
Post-Polycythemia Vera MF (Post-PV-MF)
Post-Essential Thrombocythemia MF (Post-ET-MF)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KRT-232
Best Available Therapy (BAT)
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Sponsor:
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Location:
Code:
NCT04471727
Conditions
Small-Cell Lung Cancer
Neuroendocrine Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
MK-6070
Atezolizumab
Ifinatamab Deruxtecan (I-DXd)